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surgery is the standard treatment for potentially resectable 
esophageal cancer. Patients aged over 75 years or with a 
tumor length of more than 8 cm were not included in the 
CROSS trial. In clinical practice, these patients are also 
treated according to the CROSS strategy, when considered fit 
enough. The aim of this study is to analyze the effectiveness 
and toxicity of preoperative CRT followed by resection for 
patients who do not meet the CROSS criteria because of age 
or tumor length. 
Materials and Methods; patients treated from 2005 to 
November 2013 in the Esophageal Centre East Netherlands 
according to the CROSS trial were included. Patients were 
divided into two groups; group I 'meeting criteria CROSS' 
(n=110) and group II '>75 years and or tumor length > 8 cm' 
(n=16). Primary endpoints were differences in disease 
specific and overall survival and secondary endpoints were 
toxicity, treatment interruptions and residual tumor volume 
after CRT. 
Results: in this small population, the effectiveness did not 
seem to differ between patients who did and did not meet 
the inclusion criteria of the CROSS trial. Similar disease 
specific survival rates were found, although overall survival 
was shorter for patients who were not eligible for the CROSS 
trial (3.6 vs. 6.2 years, p=0,02). Among a subgroup of 
patients aged over 75 years (n=9), more adverse effects of 
CRT were reported (89% vs 65%, relative risk 1,4 (95% CI 1,1-
1,8)), as were postoperative complications (100% vs 65%, 
relative risk 1,5 (95% CI 1,3-1,8)). Also, treatment was more 
often interrupted among older patients 33% vs 6%( relative 
risk 5,8 (95% CI 1,7-19,5)). In the subgroup tumor length > 8 
cm (n=7) we did not find a difference in toxicity. However, a 
lower percentage residual tumor after CRT was found in the 
subgroup >75 years compared to group I (50% vs 19%, relative 
risk 0,2 (95% CI 0,1-1,0)). 
Conclusions: we found no obvious differences in the 
effectiveness of preoperative CRT followed by resection 
between patients who did and did not meet the inclusion 
critera of the CROSS trial based on age and tumor length. 
Patients aged >75 years have an increased risk of adverse 
effects and postoperative complications. 
Discussion: our findings based on a retrospective evaluation 
of a small number of patients should lead to further 
prospective research. 
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Purpose/Objective: Glioblastoma multiforme (GBM) is the 
most common malignant primary brain tumor. Depending on 
the increase of elderly patient population, the incidence of 
GBM in elderly patients is rising and identification of 
prognostic factors is very important for treatment 
management. 50 years of age is considered as a prognostic 
limit for malignant gliomas. In this study, we aimed to 
evaluate clinical prognostic factors in patients aged 50 and 
older. 
Materials and Methods: Clinical prognostic factors of 73 GBM 
patients aged 50 and older, are evaluated retrospectively. 
Results: Mean survival was 5.2 months (0.1- 33.23 months). 
30 patients (41.1%) were female and 43 patients (58.9%) were 
male. Of the 73 patients, 36 (49.3%) were in the range of 50 
to 59 years old and 37 (50.7%) were aged 60 and above. 
Primary tumors were confined to a single lobe in 36 patients 
(49.3%). Nearly total resection of tumor had been performed 
in 26 patients (35.6%). Average values of tumor diameter and 
residual tumor diameter were 4.82 cm (3-8 cm) and 1 cm (0-
8cm), respectively. 31 patients (42.4%) had WHO 
performance score of 0 or 1. In univariate analysis, factors 
that affect the survival negatively were: poor WHO 
performance status (p=0.001), ≥60 age (p=0.04), ≥1cm 
residual tumor diameter (p=0.012), ≥40 days of Radiotherapy 
(RT) period (0.002),  
Conclusions: Standard treatment of GBM consists of surgery, 
radiotherapy, and chemotherapy with temozolomide. But 
optimal treatments cannot be performed in all elderly 
patients. In this study, it has been determined that the 
maximal resection (as much as possible) of the tumor affects 
significantly the survival in elderly patients. 
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Purpose/Objective: To evaluate technique, toxicity and 
results of stereotactic body radiation therapy (SBRT) for 
primary or metastatic lung tumors in patients over 75 years 
old. 
Materials and Methods: Between 2002 and 2014, 73 elderly 
patients (61 men and 12 women) with 85 lung tumors: 65 
primary and 20 oligometastatic were treated using SBRT. 
Treatment outcomes, toxicity and technique were analyzed 
retrospectively. 
SBRT involved: Computed tomography (CT) slow-scan 
simulation with immobilization devices, contouring the target 
volume in 3 sets of CTs, superimposing the volumes in the 
planning system to represent the internal target volume 
(ITV), dose calculation using heterogeneity correction and 
assuring very conformal dose distribution and a steep fall-off 
of the radiation dose outside treatment volume and radiation 
delivery with multiple static non-coplanar beams and arc 
therapy. The prescribed dose was ablative, either 3 fractions 
of 14-16 Gy each or a single 30-Gy fraction (corresponding to 
biologically equivalent doses > 100). Dose constraints were 
set for surrounding organs at risk.  Toxicity and radiologic 
response were assessed in follow-up visits, using conventional 
criteria (RTOG, EORTC scores and radiologist reviewed 
reports). Survival rates and cumulative incidences of 
toxicities were calculated by actuarial and Kaplan-Meier 
method. 
Results: Median patient age was 80 years (75-88). Before 
treatment all patients had Karnofsky Performance Scores 
